Close

Canaccord Genuity Maintains a ''Buy' on Cytokinetics (CYTK); Management Event Takeaways: CK357 Dizziness May Not Be Deal Breaker in ALS Treatment Dec 14, 2011 08:37AM
Canaccord Genuity maintains a 'Buy' on Cytokinetics (CYTK); A closer look - CK357 Dizziness: May Not Be Dealbreaker in ALS Oct 7, 2011 08:38AM
Canaccord Genuity Reiterates a 'Buy' on Cytokinetics (CYTK); Phase 2A CK357 Claudication Data: Supports Mechanism but Shows Noisy CNS Safety Profile Jun 7, 2011 08:48AM
Canaccord Genuity Reiterates a 'Buy' on Cytokinetics (CYTK); Takeaways From Meetings on the Road with Management Jun 2, 2011 08:25AM
Canaccord Genuity Maintains a 'Buy' on Cytokinetics (CYTK); CK357 Phase 2 ALS Data Well Received at AAN Plenary Apr 18, 2011 11:02AM


Feb 15, 2011 11:17AM Canaccord Genuity Maintains a 'Buy' on Cytokinetics (CYTK); New 357, Omecamtiv Phase 2 Trials to Start in 2011
Dec 13, 2010 11:09AM Canaccord Genuity Maintains a 'Buy' on Cytokinetics (CYTK); 357 Shows Benefit in Strength, Breathing, Global Asessment Endpoints Phase 2 ALS Trial
Dec 7, 2010 10:39AM Canaccord Genuity Maintains a 'Buy' on Cytokinetics (CYTK); Think CK357 Phase 1/2 ALS Efficacy Data Will Be Next Catalyst
Jun 9, 2010 10:58AM Canaccord Genuity Maintains a 'Buy' on Cytokinetics (CYTK); Claudication Data in H1/11 Likely to Drive Partner Talks